11 Worst Performing Stocks in S&P 500 So Far in 2025

Page 2 of 10

9. Viatris Inc. (NASDAQ:VTRS)

YTD Decline in Share Price: -34.54%

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that offers prescription brand drugs, complex generic drugs, and biosimilars. It also provides drugs in a variety of therapeutic areas, covering treatments of several noncommunicable and infectious diseases.

On December 23, the company announced that the FDA had restricted imports of 11 products made at Viatris Inc. (NASDAQ:VTRS)’s oral finished dose manufacturing facility in Indore, India, after a regulatory inspection found it had violated federal requirements. The FDA issued a warning letter to the company, as a result of which these products will not be accepted into the US until the warning letter is lifted.

Products affected by the import alert include lenalidomide and everolimus, with conditional exceptions granted for four products based on shortage concerns. While Viatris Inc. (NASDAQ:VTRS) continues to ship products from the Indore facility to other markets, the company expects a negative impact of $500 million on total revenue and $385 million on adjusted EBITDA for fiscal 2025.

On top of that, Viatris Inc. (NASDAQ:VTRS) reported mixed results for the fourth quarter of fiscal 2024, missing revenue and earnings expectations, while announcing significant debt reduction. Following the financial results, several rating firms, including Jefferies and Piper Sandler, cut their price targets for the stock.

Due to these developments, Viatris Inc. (NASDAQ:VTRS) has plunged 34.54% so far in 2025 and is among the worst performing stocks this year.

Page 2 of 10